All In Biotech

NDA 019955 · Ferring Pharms INC

Ddavp

Desmopressin Acetate · Oral

Last checked: Nov 20, 2026Latest source record: Feb 28, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Sep 6, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

99

23 Phase 3, 8 recruiting

FAERS reports

3,313

2,397 serious, 238 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2025.

INDICATIONS AND USAGE Central Diabetes Insipidus: Desmopressin Acetate Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: Desmopressin Acetate Tablets are indicated for the management of primary nocturnal enuresis. Desmopressin Acetate Tablets may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DDAVP · DESMOPRESSIN ACETATE 0.1MG · TABLET, ORAL · Prescription · TE AB
  • DDAVP · DESMOPRESSIN ACETATE 0.2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Desmopressin" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyponatraemia339
  • drug ineffective221
  • headache191
  • nausea181
  • fatigue145
  • off label use143
  • vomiting138
  • dizziness117
  • diarrhoea110
  • pain105
  • asthenia98
  • malaise87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200480
200563
200675
200748
2008143
2009147
2010141
2011138
2012167
2013100
2014135
2015133
2016183
2017173
2018166
2019144
2020152
2021172
2022196
2023189
2024255
2025195
2026118

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ddavp* (Desmopressin Acetate)

2024 spending

$348K

Beneficiaries

52

297 claims

Per beneficiary

$6,696

$10.04 per unit

View as table
YearSpending
2020$772,773
2021$599,706
2022$518,805
2023$420,012
2024$348,215

Part B: Ddavp* (Desmopressin Acetate*) · HCPCS J2597

2024 spending

$356K

Beneficiaries

2,151

2,468 claims

Per beneficiary

$165

2024 ASP limit $5.90 per unit

View as table
YearSpending
2020$535,096
2021$573,116
2022$461,489
2023$388,512
2024$355,880

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 683 on PubMed

Sponsor: Ferring Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.